Blister

JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)

Retrieved on: 
水曜日, 5月 29, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, JJP, Patient, EudraCT, Biology, Blister, Immunoglobulin G, European Medicines Agency, Clinical trial, Linear IgA bullous dermatosis, Doctor of Philosophy, Immunoglobulin M, Trial of the century, Autoimmunity, Disease, Safety, Henoch–Schönlein purpura, Autoantibody, Fatty liver disease, IgA nephropathy, Trust, Civil service commission, European Commission, Idiopathic pulmonary fibrosis, Cancer, CSO, Axial spondyloarthritis, Lupus, Biomarker, Incidence, Chronic obstructive pulmonary disease, Volunteering, Cystic fibrosis, Hidradenitis suppurativa, Linearity, European, Paratriathlon, Rheumatoid arthritis, Immunoglobulin A, Pharmaceutical industry

Up to date, JJP Biologics is the first Polish company to receive approval to perform the First-in-Human clinical trial with a novel therapeutic monoclonal antibody.

Key Points: 
  • Up to date, JJP Biologics is the first Polish company to receive approval to perform the First-in-Human clinical trial with a novel therapeutic monoclonal antibody.
  • According to Paweł Szczepański, COO and Management Board Member at JJP Biologics - “This is a historically unprecedented approval of a first-in-human clinical trial for a novel large molecule therapy from Poland.
  • JJP Biologics is exploring the development of companion diagnostics in various indications using serum IgA autoantibodies as biomarkers for personalized treatment with JJP-1212.
  • JJP Biologics pursues the development of its product candidates as well as projects executed in cooperation with scientific partners.

$2 Billion Blister Packaging Equipment Markets - Global Trends, Forecasts and Competitive Analysis to 2030 - ResearchAndMarkets.com

Retrieved on: 
木曜日, 5月 23, 2024
Packaging, Chemicals, Plastics, Other Manufacturing, Manufacturing, Blister, Health, Investment, Growth, Food, Porter's five forces analysis, M&A, Aluminium, Plastic, Fine chemical

The "Blister Packaging Equipment Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blister Packaging Equipment Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global blister packaging equipment market is expected to reach an estimated $2.0 billion by 2030 with a CAGR of 6.2% from 2024 to 2030.
  • The future of the global blister packaging equipment market looks promising with opportunities in the food & beverage, healthcare, cosmetic, and pharmaceutical markets.
  • Segmentation Analysis: Blister packaging equipment market size by material, technology, equipment, end use, and region in terms of value ($B).

SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy

Retrieved on: 
火曜日, 4月 16, 2024
ILC2, FDA, Idiopathic pulmonary fibrosis, Irritation, Blister, Hope, Safety, T helper cell, Animal, SAE, Research, JAK1, Immunoglobulin G, Therapy, Patient, EAACI, Clinical trial, Atopic dermatitis, Asthma, Immunity, FIC, Pharmaceutical industry

The publication in this international, peer-reviewed and well-cited journal Allergy establishes the scientific validity of SM17 on the treatment of AD, and highlights the potential of SM17 as a revolutionary product in this field.

Key Points: 
  • The publication in this international, peer-reviewed and well-cited journal Allergy establishes the scientific validity of SM17 on the treatment of AD, and highlights the potential of SM17 as a revolutionary product in this field.
  • The Allergy article and the results of the US Phase I study scientifically validated the favourable efficacies and good safety profile of SM17 for treating AD.
  • We are pleased that evidence demonstrating the advantageous therapeutic potential of SM17 for treating AD is scientifically confirmed and endorsed by being published on the renowned peer-reviewed journal Allergy.
  • The preclinical results will be confirmed in human in a proof of concept clinical trial in AD patients that was initiated in April 2024."

IBSA Introduces Two New Dietary Supplements Into the U.S. Market

Retrieved on: 
火曜日, 5月 7, 2024
Alternative Medicine, Health, Other Health, Fitness & Nutrition, Managed Care, Pharmaceutical, Selenium, FDA, Blister, Iodine, Dietary supplement, Food, IBSA, Piperine, Disease, Nutrient, Multimedia, Micronutrient, Absorption

Manufactured and marketed by IBSA, Syrel and Thirodium are select dietary supplements that contain two vital micronutrients for thyroid support – selenium and iodine respectively.

Key Points: 
  • Manufactured and marketed by IBSA, Syrel and Thirodium are select dietary supplements that contain two vital micronutrients for thyroid support – selenium and iodine respectively.
  • These new dietary supplements are the first two of the company’s line of IBSA Care products.
  • View the full release here: https://www.businesswire.com/news/home/20240506085709/en/
    Manufactured and marketed by IBSA, Syrel and Thirodium are select dietary supplements that contain two vital micronutrients for thyroid support – selenium and iodine respectively.
  • IBSA plans to add to its IBSA Care line of select dietary supplements by introducing other products later this year.

AMERICAN ACADEMY OF DERMATOLOGY SURVEY SHOWS OUTDOOR WORKERS MORE AT RISK FOR SKIN CANCER THAN AVERAGE AMERICANS

Retrieved on: 
火曜日, 5月 7, 2024
Moles, UPF, American Academy, University, Cancer, Perspiration, Blister, Carcinoma, Risk, Skin, Burn, American Academy of Dermatology, Hand, MD, Dermatology, Sunburn, Skin cancer, Life, Tanning, AAD, Melanoma, SPF, Human, Swimming, Emergency medical services, UV, Clothing, Cosmetics

ROSEMONT, Ill., May 7, 2024 /PRNewswire/ -- A recent American Academy of Dermatology survey of more than 1,000 U.S. adults revealed that outdoor workers – like those who work in construction, landscaping, emergency medical services, and postal delivery – are far more likely to get sunburned and tanned, putting themselves at increased risk for skin cancer, compared to the average American. In recognition of Skin Cancer Awareness Month this May, the AAD encourages everyone – and especially those who work outdoors – to practice safe sun to protect themselves from the sun's harmful rays and reduce their risk of developing skin cancer.

Key Points: 
  • According to the survey, half of outdoor workers were sunburned in 2023, compared to 36 percent reported by the general American population.
  • One in 10 outdoor workers had sunburns severe enough to cause blisters, a rate double that of the general population.
  • And nearly 80 percent of outdoor workers got a tan or darker skin as a result of sun exposure, compared to 67 percent of Americans overall.
  • Tanning and unprotected sun exposure are major risk factors for skin cancer, the most common form of cancer in the United States and one of the most preventable types of cancer.

Pharmaceutical Packaging Market to Be Worth $176.54 Billion by 2031 - Exclusive Report by Meticulous Research®

Retrieved on: 
金曜日, 5月 3, 2024
PFS, United Nations, Polyvinyl chloride, Investment, PP, Ampoule, PVC, Polymer, Medicine, Paper, AptarGroup, Gas, Sachet, Blister, Drug discovery, PET, Inhaler, Catalent, Drug packaging, Cellulose, Tablet, Corning Inc., Regulation (European Union), Conditional sentence, Research, Transport, Carbon, QR, Shield, Government, WestRock, Polyethylene, Capsule, Syringe, Glass, Route of administration, Environment, United, Amcor, Growth, Fine chemical

Pharmaceutical companies are increasingly focusing on sustainable pharmaceutical packaging in order to cut waste and reduce their carbon footprint.

Key Points: 
  • Pharmaceutical companies are increasingly focusing on sustainable pharmaceutical packaging in order to cut waste and reduce their carbon footprint.
  • Key findings in the pharmaceutical packaging market report:
    Among all the materials studied in this report, in 2024, the polymer segment is expected to account for the largest share of 43% of the pharmaceutical packaging market.
  • Among all the packaging types studied in this report, in 2024, the primary packaging segment is expected to account for the largest share of 72% the pharmaceutical packaging market.
  • However, Asia-Pacific pharmaceutical packaging market is expected to growth with the highest CAGR of 8.5% over the forecast period.

Pharmaceutical Packaging Market to Be Worth $176.54 Billion by 2031 - Exclusive Report by Meticulous Research®

Retrieved on: 
金曜日, 5月 3, 2024
PFS, United Nations, Polyvinyl chloride, Investment, PP, Ampoule, PVC, Polymer, Medicine, Paper, AptarGroup, Gas, Sachet, Blister, Drug discovery, PET, Inhaler, Catalent, Drug packaging, Cellulose, Tablet, Corning Inc., Regulation (European Union), Conditional sentence, Research, Transport, Carbon, QR, Shield, Government, WestRock, Polyethylene, Capsule, Syringe, Glass, Route of administration, Environment, United, Amcor, Growth, Fine chemical

Pharmaceutical companies are increasingly focusing on sustainable pharmaceutical packaging in order to cut waste and reduce their carbon footprint.

Key Points: 
  • Pharmaceutical companies are increasingly focusing on sustainable pharmaceutical packaging in order to cut waste and reduce their carbon footprint.
  • Key findings in the pharmaceutical packaging market report:
    Among all the materials studied in this report, in 2024, the polymer segment is expected to account for the largest share of 43% of the pharmaceutical packaging market.
  • Among all the packaging types studied in this report, in 2024, the primary packaging segment is expected to account for the largest share of 72% the pharmaceutical packaging market.
  • However, Asia-Pacific pharmaceutical packaging market is expected to growth with the highest CAGR of 8.5% over the forecast period.

New multi-stakeholder industry initiative launched in the UK to take collaborative action on recycling of primary pharmaceutical packaging

Retrieved on: 
水曜日, 5月 1, 2024
NHS, Public affairs, Nature, Climate, Health, OTC, Blister, Vaccine, Patient, Communication, Recycling, Pharmaceutical industry

CHELTENHAM, England, May 1, 2024 /PRNewswire/ -- The Circularity in Primary Pharmaceutical Packaging Accelerator (CiPPPA) initiative launched this week to tackle the challenges of recycling medicinal devices and pharmaceutical packaging.

Key Points: 
  • CHELTENHAM, England, May 1, 2024 /PRNewswire/ -- The Circularity in Primary Pharmaceutical Packaging Accelerator (CiPPPA) initiative launched this week to tackle the challenges of recycling medicinal devices and pharmaceutical packaging.
  • The pharmaceutical industry faces recycling difficulties due to regulations and complex materials, and CiPPPA aims to enhance pharmaceutical packaging's end-of-life management to reduce waste and promote environmental stewardship.
  • Major pharmaceutical companies, global over-the-counter (OTC) brands, and healthcare systems like the NHS have joined the initiative, demonstrating a collective commitment to driving environmental and societal change.
  • By founding and establishing CiPPPA, we are able to deliver enhanced end-of-life for blister packs and related pharmaceutical packaging such as metered dose inhalers and injectables.

Public Advisory - Fake Viagra seized from Jug City store in Scarborough, ON

Retrieved on: 
金曜日, 4月 26, 2024
Sale, Pharmacy, Stroke, Safety, Risk, Hearing loss, Nitroglycerin, Natural product, Health, Dizziness, Health Canada, Plasma protein binding, Blister, Counterfeit, Policy, NPN, Prescription drug, Headache, Counterfeit medications, Chest pain, DIN, Dietary supplement

Health Canada has seized counterfeit Viagra from a Jug City store in Scarborough, Ontario (96 Dearham Wood).

Key Points: 
  • Health Canada has seized counterfeit Viagra from a Jug City store in Scarborough, Ontario (96 Dearham Wood).
  • This is in addition to several other unauthorised sexual enhancement products seized from the same store.
  • For more information regarding Health Canada's approach to counterfeit health products, please consult Health Canada's Policy on Counterfeit Health Products .
  • Authorized health products have an eight-digit Drug Identification Number (DIN), Natural Product Number (NPN) or Homeopathic Drug Number (DIN-HM).

Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products

Retrieved on: 
金曜日, 4月 12, 2024
USD, Negotiation, Organization, Pharmacy, Production, Blister, Republic, Certification, OTC, Thought, Plant, Erectile dysfunction, Ministry, Marketing, Good, GMP, ED, Bioequivalence, Pharmaceutical industry

Dallas, Texas, April 12, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce that its subsidiary, MangoRx Mexico S.A. de C.V. (“MangoRx Mexico”), has secured and executed a technical agreement with Emifarma S.A. de C.V (“Emifarma”) for the initial stages of development and testing (Bioequivalence and Accelerated Stability, required to obtain registry from COFEPRIS) of the Company’s Mango ED products intended for the Mexican and Latin American markets.

Key Points: 
  • Founded in 1998 by a group of pharmaceutical professionals with experience in Development, Production and Quality, Emifarma is a Mexican company that employs more than 100 workers and has 4 plants that specialize in: Hormonal, Injectable, Additive and Oral Solid (tablet and powdered) products where they serve as a manufacturing partner for some of the most relevant pharmaceutical companies both domestically and internationally, operating in Mexico.
  • Emifarma is Certified for Good manufacturing Practices (GMP) by the following organizations: COFEPRIS, INVIMA, Ministry of Health of the Republic of Peru.
  • Specifically, COFEPRIS is recognized in the following additional countries: Columbia, Ecuador, El Salvador, Chile, Costa Rica and Panama.
  • Efi Karchmer, President of MangoRx Mexico stated, “after visiting, interviewing, and negotiating with many different pharmaceutical manufacturing companies over the past several months, we are very excited about our decision to partner with Emifarma in this endeavor.